The Goldman Sachs Group Inc
(MEX:GS)
MXN
18,984.54
-366.29 (-1.89%)
Market Cap: 5.58 Tn
Enterprise Value: 10.22 Tn
PE Ratio: 19.68
PB Ratio: 2.91
GF Score: 51/100 Kronos Bio, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-15-2023 10:40 AM Transcript
Jun 15, 2023 / 05:40PM GMT
Release Date Price:
MXN5854
(+1.12%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP
Great. Good morning, everyone. Thanks for joining us. Really pleased to have with us the Kronos team. We have Norbert Bischofberger, President and CEO; Yasir Al-Wakeel, CFO and Head of Corporate Development; and Jorge DiMartino...
Charles Lin
Kronos Bio, Inc. - SVP of Biology
I'm Charles.
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP
Actually, Charles. sorry.
Charles Lin
Kronos Bio, Inc. - SVP of Biology
Jorge couldn't make it.
Questions & Answers
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP
Yes. Yes. Yes. So maybe to start here. KB-0742, your CDK inhibitor, is the first molecule to emerge from your platform. Can you start by walking through the key takeaways for the first -- from the first data release that you provided as well as the rationale for your Phase II dose selection?
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot